Infectious Disease Book

http://www.fpnotebook.com/

Respiratory Syncytial Virus VaccineAka: RSV Vaccine, Palivizumab, Synagis

Advertisement

  1. Mechanism
    1. Humanized mouse Monoclonal Antibody to RSV
  2. Indications: Based on AAP guidelines
    1. Chronic lung disease in age <2 years
      1. Medication treatment within 6 months of RSV season start
    2. Hemodynamically significant Congenital Heart Disease in age <2 years
    3. Consider in infants with severe Immunodeficiency
    4. Preterm Infants during their first RSV season
      1. Gestational age at birth <28 weeks (Give during first RSV season)
      2. Gestational age at birth 28-32 weeks who are under age 6 months during RSV season
      3. Gestational age 32-35 weeks with 2 risk factors:
        1. Child care attendance
        2. School-aged siblings
        3. Environmental pollution exposure
        4. Airway abnormality
        5. Severe neuromuscular disease
  3. Dosing
    1. Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)
  4. Efficacy
    1. Decreases hospitalizations by 45 to 55%

palivizumab (C0672596)

Definition (NCI)A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylaxis application of Respiratory Syncytial Virus infections. RSV F protein, a small envelop glycoprotein, not only is required for cytopathic syncytia resulted from cell-to-cell fusion, but also is necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibit fusion activity of RSV, thereby prevent the syncytia formation. Administration of this antibody does not interfere with other immunization.
ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
EnglishPALI, palivizumab, PALIVIZUMAB PREPARATION
Spanishpalivizumab
CreditsDerived from the NIH UMLS (Unified Medical Language System)


Synagis (C0723567)

ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
EnglishAbbott brand of palivizumab, MedImmune brand of palivizumab, Synagis
CreditsDerived from the NIH UMLS (Unified Medical Language System)


Respiratory Syncytial Virus Vaccines (C0887894)

Definition (MSH)Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
ConceptsPharmacologic Substance (T121) , Immunologic Factor (T129)
EnglishRespiratory Syncytial Virus Vaccines, RSV Vaccines
CreditsDerived from the NIH UMLS (Unified Medical Language System)



Navigation Tree